Health and Healthcare

All Health and Healthcare Articles

Newest first · Page 369

Looking Beyond Dendreon’s Upcoming Earnings Release (DNDN)

Dendreon Corp. (NASDAQ:DNDN) will release earnings next Tuesday, August 7, after the close.  The volatility in shares has dried up considerably as shares have only traded above $8.00 or below $7.00 for part of…

Douglas A. McIntyre · 19 years ago

Pfizer’s (PFE) Bad Hair Day

Not a good quarter for Pfizer (PFE). Second quarter revenue fell 6% to $11.1 billion. Net income was down 48% to $1.3 billion. The loss of U.S. exclusivity for Zoloft and Norvasc hurt earnings…

Douglas A. McIntyre · 19 years ago

Dendreon: A New Form of Shareholder Activism (DNDN)

There was a bit of an unusual message this morning, and that was an advertisement about Dendreon’s (NASDAQ:DNDN) Provenge in the Sunday edition of The Washington Post.  Yet it apparently isn’t from the company…

Douglas A. McIntyre · 19 years ago

Dendreon’s New Hurdle: The SEC (DNDN)

It appears that Dendreon (NASDAQ:DNDN) may be an SEC target now, or at least it is going to get the pleasure of dealing with the SEC for a while.  The New York regional office…

Douglas A. McIntyre · 19 years ago

Dendreon Options Trading: Hope or Hearsay?

Dendreon (DNDN-NASDAQ) is trading up almost another 2% pre-market after Tuesday options activity had shares up $0.47 to close at $7.70 per share.  The shares actually hit as high as $8.30 on Tuesday, which…

Douglas A. McIntyre · 19 years ago

CryoCor Regains Lost Ground; FDA Remains Unpredictable (CRYO)

CryoCor Inc. (CRYO-NASDAQ) is trading up almost 100% in early trading today.  Last night the company announced that an FDA Advisory Panel had recommended backing the company’s pre-market approval application for the company’s treatment…

Douglas A. McIntyre · 19 years ago

Mixed Short Interest in Drug & Medical Stocks (June 2007)

As you will see, the short interest changes in medical and drug stocks of the active NYSE-listed names was a bit of a mixed bag.  GlaxoSmithkline (GSK) saw the lagest increase, but its short…

Douglas A. McIntyre · 19 years ago

Orexigen Therapeutics: Tricking the Mind Out of Being Fat (OREX)

Orexigen Therapeutics, Inc. (OREX-NASDAQ), a biopharmaceutical with an initial focus on obesity, has announced that data presented today at the American Diabetes Association 67th Scientific Sessions in Chicago from a sub-study of its Phase…

Douglas A. McIntyre · 19 years ago

Obama & Clinton Criticize Bush Stem Cell Veto (STEM, GERN, ASTM)

Stock Tickers: STEM, GERN, ASTM Senator Obama has issued a statement regarding President Bush’s veto of the Embryonic Stem Cell Bill: Senator Obama noted:  "By vetoing funding for stem cell research once again, the…

Douglas A. McIntyre · 19 years ago

Biotech Implosion: Coley Pharmaceutical Group (COLY)

Shares of microcap biotech Coley Pharmaceutical Group (COLY-NASDAQ) saw shares get pounded late on Wednesday afternoon.  Right before 2:00 PM EST, the company announced that its partner Pfizer (PFE-NYSE) had discontinued and exited its…

Douglas A. McIntyre · 19 years ago

Biotech Implosion: Allos Therapeutics (ALTH)

Allos Therapeutics, Inc. (ALTH-NASDAQ) is indicated down almost 20% in thin pre-market trading after it announced that top line results from ENRICH, the Company’s pivotal Phase III study of EFAPROXYN plus whole brain radiation…

Douglas A. McIntyre · 19 years ago

IPO Filing: MAP Pharmaceuticals, the New Inhaler

A new inhaled-molecule company named MAP Pharmaceuticals, Inc. has filed for an IPO.  Underwriters are listed as Merrill lynch, Morgan Stanley, and Deutsche Bank.  It has a proposed stock ticker of "MAPP" on NASDAQ.…

Douglas A. McIntyre · 19 years ago